Heterocyclic compounds as ERK inhibitors

US8999957B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Yongqi Deng · Newton, US
• Liang Zhu · Waltham, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Sie-Mun Lo · Springfield, US
• Binyuan Sun · Sharon, US
• Xiaohua Huang · Qingdao, CN
• Corey E. Bienstock · Natick, US
• Alan B. Cooper · West Caldwell, US
• Xiaolei Gao · Bound Brook, US
• Xin Yao · Beijing, CN
• Hugh Y. Zhu · Scotch Plains, US
• Joseph M. Kelly · Sayreville, US
• Sobhana Babu Boga · Scotch Plains, US
• Abdul-Basit Alhassan · Scotch Plains, US
• Jayaram R. Tagat · Westfield, US
• Umar Faruk Mansoor · Framingham, US
• Kevin J. Wilson · Boston, US
• Brendan M. O'Boyle · Boston, US
• Matthew H. Daniels · Somerville, US
• Adam J. Schell · Decatur, US
• Phieng Siliphaivanh · Newton, US
• Christian Fischer · Natick, US

Key dates

• Filing date: Jun 22, 2011
• Grant date: Apr 7, 2015
• Expiry date: Jul 8, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/1804
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.